JAK2 and breast carcinoma: In contrast to the well-established signaling pathway activation mediated by EPO-EPOR in hematopoietic cells, EPO treatment of mammary carcinoma cells did not induce the phosphorylation of the JAK2/STAT5 axis- a critical pathway for physiologic EPOR function in hematopoietic cells [41].